Baseline parameter (mean ± SD) | Canocapavir | Placebo n = 6 | ||
---|---|---|---|---|
50 mg n = 8 | 100 mg n = 8 | 200 mg n = 8 | ||
Age, years | 36.9 (9.08) | 36.9 (6.15) | 41.8 (10.91) | 47.7 (10.86) |
Sex (male/female) | 6/2 | 3/5 | 6/2 | 4/2 |
Ethnicity (Han/other) | 8/0 | 7/1 | 8/0 | 6/0 |
Weight (kg) | 67.60 (10.645) | 54.20 (7.648) | 71.43 (6.443) | 69.48 (7.51) |
HBV DNA (log10 IU/mL) | 6.68 (1.64) | 7.16 (1.52) | 6.04 (1.84) | 6.42 (2.07) |
HBV pgRNA (log10 copies/mL) | 6.04 (1.66) | 5.60 (1.68) | 5.10 (2.00) | 5.14 (2.79) |
HBcrAg (log10 Ku/mL) | 3.98 (2.16) | 4.38 (1.86) | 3.29 (2.04) | 2.99 (2.45) |
HBsAg (log10 IU/mL) | 4.23 (0.62) | 4.10 (1.00) | 3.97 (0.75) | 3.79 (1.17) |
HBeAg (log10 PEI-U/mL) | 3.06 (0.09) | 3.09 (0.22) | 2.05 (1.42) | 2.77 (0.43) |
HBeAg (positive/negative) | 5/3 | 5/3 | 4/4 | 3/3 |
Fibroscan (kPa) | 5.05 (0.42) | 5.41 (2.18) | 5.54 (1.10) | 5.05 (1.01) |
ALT (U/L) | 30.89 (18.95) | 46.65 (42.72) | 41.13 (14.62) | 35.98 (19.16) |
AST (U/L) | 27.09 (9.48) | 52.61 (46.25) | 33.06 (9.97) | 30.75 (8.16) |
genotype | B = 3; C = 5 | B = 2; C = 6 | B = 1; C = 7 | B = 3; C = 3 |